

Increase Access to the Agency's Compliance and Enforcement Data," as part of the Transparency Initiative. This report includes eight initiatives adopted by the Commissioner of Food and Drugs (the Commissioner) to explore avenues for making FDA's publicly available compliance and enforcement data more accessible and user-friendly.

FOR FURTHER INFORMATION CONTACT: Daniel W. Sigelman, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 4254, Silver Spring, MD 20993, 301-796-4706, Fax: 301-847-8616, email: daniel.sigelman@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a report entitled "Food and Drug Administration Transparency Initiative: Exploratory Program to Increase Access to the Agency's Compliance and Enforcement Data." FDA is responsible for a broad range of compliance and enforcement activities. Increasing the transparency of these activities enhances the public's understanding of the Agency's decisions and promotes accountability of the Agency and the regulated industry.

In a May 6, 2011, memorandum to the Department of Health and Human Services responding to a January 18, 2011, Presidential Memorandum on Regulatory Compliance, (76 FR 3825, January 21, 2011), FDA recounted the actions it had already implemented, as well as those proposed or underway, to increase public accessibility of its regulatory compliance and enforcement information. FDA stated that it would: (1) Issue proposals for public comment within 150 days (by October 3, 2011) if

it concluded that there were additional opportunities to increase the transparency of its compliance and enforcement data, and (2) determine within 270 days (by January 31, 2012) whether to adopt such proposals.

On October 3, 2011, FDA issued a report entitled "Food and Drug Administration Transparency Initiative: Draft Proposals for Public Comment to Increase Transparency by Promoting Greater Access to the Agency's Compliance and Enforcement Data," that advanced eight draft proposals to make FDA's publicly available compliance and enforcement data more accessible and user-friendly (<http://www.fda.gov/downloads/AboutFDA/Transparency/TransparencyInitiative/UCM273145.pdf>). In publishing a notice of availability of this report on October 4, 2011 (76 FR 61366), FDA sought public comment on these proposals by December 2, 2011. The Agency stated that its Transparency Task Force would ultimately recommend specific draft proposals to the Commissioner for consideration based on the comments it received, the feasibility of each draft proposal, relative priority, and available resources, and that the Commissioner would determine whether to adopt any of these draft proposals by January 31, 2012.

Based on a review of the recommendations of the Transparency Task Force, the Commissioner is adopting all eight of the draft proposals published in October 2011 as initiatives the Agency will explore, thereby committing the Agency to investigating numerous avenues for increasing the transparency and public accessibility of its compliance and enforcement data.

Dated: January 27, 2012.

David Dorsey,

Acting Associate Commissioner for Policy and Planning.

[FR Doc. 2012-2184 Filed 1-31-12; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0003]

Withdrawal of Approval of New Animal Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 20 new animal drug applications (NADAs) at the sponsor's request because the products are no longer manufactured or marketed.

DATES: Withdrawal of approval is effective February 13, 2012.

FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, email: john.bartkowiak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The following sponsors have requested that FDA withdraw approval of the 20 NADAs listed in table 1 of this document because the products are no longer manufactured or marketed:

TABLE 1—NADAs FOR WHICH APPROVAL IS VOLUNTARILY WITHDRAWN

Application No.	Trade name (drug)	Applicant
NADA 014-485	METOPHANE Inhalation (methoxyflurane)	Medical Developments, International Ltd., 556 Morris Ave., Summit, NJ 07901-1330.
NADA 032-322	LIQUISONE F with Cerumene (hexamethyltetraacosane, prednisolone, tetracaine, neomycin sulfate).	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 044-655	NEOMYCANE Ophthalmic Ointment (neomycin sulfate)	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 045-288	OPTISONE (neomycin sulfate, prednisolone acetate)	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 049-890	NORCO T-2 Pre-Pak (tylosin phosphate)	Norco Mills of Norfolk, Inc., P.O. Box 56, Norfolk, NE 68701.
NADA 055-034	CHLORASOL (chloramphenicol)	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 055-052	Chlora-Tabs 100 (chloramphenicol)	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 065-158	CHLORICOL (chloramphenicol)	Evsco Pharmaceuticals, An Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 065-259	CHLORASONE Ophthalmic Ointment (chloramphenicol, prednisolone acetate).	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 065-488	BENZA-PEN (penicillin G benzathine, penicillin G procaine)	Walco International, Inc., 15 West Putnam, Porterville, CA 93257.

TABLE 1—NADAs FOR WHICH APPROVAL IS VOLUNTARILY WITHDRAWN—Continued

Application No.	Trade name (drug)	Applicant
NADA 095–953	MOORMABOOST TY 4000 Medicated (tylosin phosphate) ..	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 100–689	DIFIL Syrup (diethylcarbamazine citrate)	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 100–690	DIFIL Tablets (diethylcarbamazine citrate)	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 107–957	TYLAN 20 Sulfa-G (tylosin phosphate and sulfamethazine)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 111–069	TYLAN 40 Sulfa-G (tylosin phosphate and sulfamethazine)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 131–956	TYLAN Sulfa-G (tylosin phosphate and sulfamethazine)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 131–957	TYLAN 40 (tylosin phosphate)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 133–490	Ban-D–Wormer II BANMINTH (pyrantel tartrate)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 140–842	HYGROMIX 2.4 Premix (hygromycin B)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 140–958	EQUIPHEN Paste (phenylbutazone)	Luitpold Pharmaceuticals, Inc., Animal Health Division, Shirley, NY 11967.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 014–485, 032–322, 044–655, 045–288, 049–890, 055–034, 055–052, 065–158, 065–259, 065–488, 095–953, 100–689, 100–690, 107–957, 111–069, 131–956, 131–957, 133–490, 140–842, and 140–958, and all supplements and amendments thereto, is hereby withdrawn, effective February 13, 2012.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these applications.

Dated: January 26, 2012.

Bernadette Dunham,
Director, Center for Veterinary Medicine.

[FR Doc. 2012–2109 Filed 1–31–12; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Perinatal HIV-Infected Youth.

Date: February 22, 2012.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Rita Anand, Ph.D., Scientific Review Officer Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01 Bethesda, MD 20892, (301) 496–1487, anandr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: January 24, 2012.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–2189 Filed 1–31–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group, DCLG Meeting.

Date: February 29–March 1, 2012.

Time: 9 a.m. to 1 p.m.

Agenda: 2/29—Drug Shortage—A Critical Challenge for the Cancer Community; Cancer Drug Shortages: Economic, Regulatory, and Manufacturing Issues; The Role of the Cancer Advocacy Community 3/01—Advocate Engagement at the National Cancer Institute.

Place: National Institutes of Health, Building 16, 1st Floor, 16 Center Drive, Bethesda, MD 20892.

Contact Person: Amy Bulman, Acting Director, Office of Advocacy Relations, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 10A30, Bethesda, MD 20892, 301–496–9723.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the